Transgene: Building A Strong Immunotherapy Portfolio
Edison | Jul 18, 2017 06:25AM ET
Combinations with immunotherapies are key to Transgene’s (PA:TRNG) strategy. The company is focused on combining its main assets, TG4010 (cancer vaccine) and Pexa-Vec (oncolytic virus), with immune checkpoint inhibitors (ICIs), ipilimumab (Yervoy) and nivolumab (Opdivo). ICIs as monotherapies have proven successful in patients; however, positive efficacy has been limited to certain cancers and long-term responses remain difficult. Combinations with other immunotherapies may improve both addressable population and long-term efficacy. To this end, Transgene is conducting Phase I and II trials in collaboration with academic institutions and pharmaceutical companies. The first read-outs are expected later this year. Our updated valuation is €208m.
Combination trials underway and planned
Lead assets TG4010 and Pexa-Vec are in two ongoing trials with nivolumab (second-line non-small cell lung cancer (NSCLC) in collaboration with Bristol-Myers Squibb (BMS) and UC Davis) and ipilimumab (solid tumours) respectively, with both expected to read out by year end. A Phase II trial of TG4010, in combination with nivolumab and chemotherapy (in collaboration with BMS), in first-line NSCLC patients with low or undetectable PD-L1 levels is due to start by end 2017 and read out in 2018. Pexa-Vec plus nivolumab will shortly start patient enrolment in a Phase II trial for patients with first-line hepatocellular carcinoma (HCC). A Phase I/II trial of TG4001 in combination with avelumab (PD-L1 ICI) in HPV-positive head and neck cancer (HNSCC) in collaboration with Merck (NYSE:MRK) and Pfizer (NYSE:PFE) will commence in H217.
To read the entire report Please click on the pdf File Below:
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.